TABLE 2.
Phenotype comparison of AAV2 HI loop capsid mutants
| Mutant | Sequence | Assembly (Western dot blotting) | Packaging (DNA dot blotting) | Heparin binding | Infectivitya (luciferase assay) | Alternative VP1 (Western blotting) |
|---|---|---|---|---|---|---|
| AAV2 HI−/− | (655) ANP----------SFI | −e | − | NAf | NA | NA |
| AAV2 poly-glycine | (655) ANP GGGGGGGGGG SFI | +c | − | + | NA | − |
| AAV2 G661F | (655) ANP GGGFGGGGGG SFI | + | − | NDg | NA | ND |
| AAV2 G665K | (655) ANP GGGGGGGKGG SFI | + | − | ND | NA | ND |
| AAV2 G666F | (655) ANP GGGGGGGGFG SFI | + | − | ND | NA | ND |
| AAV2 HI1 | (655) ANP PAEFSATKFA SFI | + | + | + | No change | − |
| AAV2 HI8 | (655) ANP PTTFNSQKLN SFI | + | + | + | No change | − |
| AAV2 HI4 | (655) ANP ATTFSSTPVN SFI | + | − | + | No change | − |
| AAV2 HI5 | (655) GNI T-SFSDVPVS SFI | − | − | NA | NA | NA |
| AAV2 RGD 658 | (655) ANP RGDFSAAKFA SFI | + | + | ND | No change | − |
| AAV2 RGD 660 | (655) ANP STRGDAAKFA SFI | + | ±d | ND | 4.7 | + |
| AAV2 RGD 662 | (655) ANP STTFRGDKFA SFI | + | + | ND | No change | − |
| AAV2 RGD 663 | (655) ANP STTFSRGDFA SFI | + | ± | ND | No changeb | − |
| AAV2 VNTANST | (655) ANP VNTANSTKFA SFI | + | ± | + | 27 | + |
| AAV2 QPEHSST | (655) ANP QPEHSSTKFA SFI | + | + | + | 2 | + |
| AAV2 SIGYPLP | (655) ANP SIGYPLPKFA SFI | + | ± | ND | 10.4 | + |
| AAV2 SGRGDS | (655) ANP SGRGDSAKFA SFI | + | ± | ND | 4.5 | + |
| AAV2 F661G | (655) ANP STTGSAAKFA SFI | + | ± | + | 13.55 | + |
a
Relative (n-fold) decrease in infectivity.
b
In SK-OV3 cells.
c
+, similar to WT.
d
±, packaging, approximately fivefold lower in titer than WT.
e
−, packaging, 1 log lower in titer than WT or unable to package the viral genome.
f
NA, not applicable.
g
ND, not determined.